|
Autor/a:
|
Cullell, Natalia; Carrera, Caty; Muiño, Elena; Torres-Aguila, Nuria-Paz; Cárcel-Márquez, Jara; González-Sánchez, Jonathan; Gallego Fabrega, Cristina; Molina, Jessica; Besora, Sarah; Sotoca, Javier; Buongiorno, Maria-Teresa; Jiménez-Conde, Jordi; Giralt-Steinhauer, Eva; de Torres-Chacón, Reyes; Montaner, Joan; Mancha, Fernando; Cabezas, Juan A.; Martí Fàbregas, Joan; Prats Sánchez, Luis; Camps Renom, Pol; Purroy Garcia, Francisco; Cambray Carner, Serafí; Freijo, María del Mar; Vives-Bauzá, Cristòfol; Tur, Silvia; Font, Maria-Àngels; López-Cancio, Elena; Hernandez-Perez, Maria; Obach, Victor; Calleja, Ana; Arenillas, Juan; Rodríguez-Yáñez, Manuel; Castillo, José; Sobrino, Tomas; Fernández-Cádenas, Israel; Krupinski, Jerzy
|
|
Notas:
|
Acenocoumarol is an oral anticoagulant with significant interindividual dose variations. Variants in CYP2C9 and VKORC1 have been associated with acenocoumarol maintenance dose. We analysed whether any of the 49 polymorphisms in CYP2C9 and VKORC1 previously associated with acenocoumarol maintenance dose in a Genome-Wide Association study (GWAs) in Dutch population are associated with stroke recurrence, intracranial haemorrhage (ICH) and acenocoumarol maintenance dose in a Spanish population. We performed a GWAs using Human Core Exome-chip (Illumina) in 78 patients stroke patients treated with acenocoumarol for secondary prevention enrolled as part of the prospective investigator-initiated study (IIS) SEDMAN Study. Patients were followed-up a median of 12.8 months. Three and eight patients had recurrent stroke and ICH events, respectively. We found 14 of the 49 published variants associated with acenocoumarol maintenance dose (p < 0.05). Six polymorphisms were associated with stroke recurrence and four variants with ICH (p < 0.05). In conclusion, variants in VKORC1 and CYP2C9 are associated with acenocoumarol maintenance dose, stroke recurrence and ICH in a Spanish cohort. These results highlight the relevance of studying pharmacogenetics associated with efficacy and safety of anticoagulant drugs and justify studies with larger sample size and different ethnic populations.
We would like to thank the International Stroke Genetics Consortium, the Spanish Stroke Genetics Consortium, and the RETICS Network INVICTUS plus (RD16/0019/0001, RD16/0019/0002, RD16/0019/0007, RD16/0019/0010, and RD16/0019/0011, RD16/0019/0017, RD16/0019/0019 and RD16/0019/0021). |
